Supplementary Table S1 from Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non–Hodgkin Lymphoma (CAPITAL)
Year: 2026
Type: supplementary-materials
Abstract: Table discussing representativeness of the population in the trial
Authors: Daniel J. Hodson, Geoffrey Shouse, Ho-Jin Shin, Antonio Salar, Sabela Bobillo, Vincent Ribrag, Nicol A. Macpherson, Raul Cordoba, Jin Seok Kim, Stephanie Guidez, Alex F. Herrera, Franck Morschhauser, Dachelle Colton, Macarena Izuzquiza, Nisha Sambamurthy, Veerendra Munugalavadla, Sergio Vicente, Gullu Gorgun, Robert Chen, Anas Younes, Michael L. Wang
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7133221769